JM, W., M, T., TP, R., SM, P., J, S., S, P., & JF, L. (2012). Targeting the kidney and glucose excretion with dapagliflozin: Preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Dove Medical Press.
Style de citation Chicago (17e éd.)JM, Whaley, Tirmenstein M, Reilly TP, Poucher SM, Saye J, Parikh S, et List JF. Targeting the Kidney and Glucose Excretion with Dapagliflozin: Preclinical and Clinical Evidence for SGLT2 Inhibition as a New Option for Treatment of Type 2 Diabetes Mellitus. Dove Medical Press, 2012.
Style de citation MLA (8e éd.)JM, Whaley, et al. Targeting the Kidney and Glucose Excretion with Dapagliflozin: Preclinical and Clinical Evidence for SGLT2 Inhibition as a New Option for Treatment of Type 2 Diabetes Mellitus. Dove Medical Press, 2012.